Augmentation of anti-MDA5 antibody implies severe disease in COVID-19 patients
Data Availability
In this retrospective study of adult inpatients in three hospitals in China, we identified anti-MDA5 Ab in 48.2% of patients with COVID-19. The anti-MDA5 Ab positive patients tended to represent with severe disease (88.6% vs 66.9%, P<0.0001), and the titer of anti-MDA5 Ab was significantly elevated in the non-survivals (P=0.030) than that in the survivals. We also demonstrated that early profiling of anti-MDA5 Ab could distinguish severe patients from those with non-severe ones. Overall, our data suggest that early screening and serially monitoring of anti-MDA5 Ab might help identify severe COVID-19 patients with poor outcomes, or those who would probably benefit from anti-inflammation and immunosuppressive therapy. The findings are yet to be validated in a larger population of different ethnicities in future.
Subject Area
- Addiction Medicine (357)
- Allergy and Immunology (681)
- Anesthesia (182)
- Cardiovascular Medicine (2697)
- Dermatology (231)
- Emergency Medicine (406)
- Epidemiology (12336)
- Forensic Medicine (10)
- Gastroenterology (773)
- Genetic and Genomic Medicine (4181)
- Geriatric Medicine (393)
- Health Economics (690)
- Health Informatics (2704)
- Health Policy (1011)
- Hematology (366)
- HIV/AIDS (865)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (446)
- Neurology (3962)
- Nursing (216)
- Nutrition (587)
- Oncology (2090)
- Ophthalmology (597)
- Orthopedics (245)
- Otolaryngology (309)
- Pain Medicine (254)
- Palliative Medicine (76)
- Pathology (474)
- Pediatrics (1136)
- Primary Care Research (464)
- Public and Global Health (6596)
- Radiology and Imaging (1431)
- Respiratory Medicine (879)
- Rheumatology (416)
- Sports Medicine (347)
- Surgery (458)
- Toxicology (56)
- Transplantation (192)
- Urology (170)